Clinical trial Recruiting at 1 site Observational Ages 5 to 17

Evaluating gene expression changes in children on antipsychotic medications

Official title: Pilot Study of Transcriptomic Alterations Associated with Antipsychotic-induced Metabolic Disorders in Children and Adolescents

Run by IRCCS Eugenio Medea · NCT06814314 · Data updated 2026-11-12

This study is trying to see how antipsychotic medications affect the genes of children and teens with metabolic disorders, compared to those who don't take these medications, to find early signs of possible health issues.

Quick facts

Study typeObservational
Ages5 Years to 17 Years
SexAll
Enrollment100 (estimated)
SponsorIRCCS Eugenio Medea
Academic / other
Locations1 site (Bosisio Parini, LC)
StatusRecruiting
StartedApril 30, 2023
Main results expectedMay 2026
Study endsMay 2026
Registry record updatedFebruary 7, 2025
Trial IDNCT06814314 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children and adolescents aged 5-17 who are either using antipsychotics with metabolic disorders, using antipsychotics without metabolic disorders, or not using antipsychotics but have metabolic disorders.

Probably not a fit

Patients with diagnosed genetic conditions that affect energy metabolism or nutrition may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the transcriptomic profiles of children and adolescents aged 5-17 who are undergoing treatment with antipsychotic drugs and exhibit metabolic disorders. It will compare these profiles with those of similar patients who do not use antipsychotics but have metabolic disorders, as well as those who use antipsychotics without metabolic disorders. The goal is to identify distinct transcriptomic markers that could serve as early indicators of metabolic complications due to antipsychotic treatment, potentially improving management strategies for these therapies.

Why it matters

Potential benefit: If successful, this study could lead to the identification of biomarkers that help predict metabolic disorders in patients treated with antipsychotics, enhancing patient care.

How similar studies have gone: While there is existing literature on the metabolic effects of antipsychotics, this specific approach of using transcriptomics to identify biomarkers is relatively novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* age 5-17 years;
* group 1: antipsychotic users with metabolic disorders;
* group 2: antipsychotic users without metabolic disorders;
* group 3: non-antipsychotic users with metabolic disorders. The definition of antipsychotic use includes daily use for at least 3 months prior to enrollment.

The definition of metabolic disorders includes: BMI-Z for age, sex and height \> +1 Waist circumference \> 90th percentile for age, sex and height Diastolic or systolic blood pressure \> 90th percentile for age, sex and height Fasting blood glucose \> 99 mg/dl Fasting triglycerides \> 149 mg/dl Fasting cholesterol \< 41 mg/dl.

Patients with metabolic disorders are defined as those who meet at least one of the above criteria.

Patients without metabolic disorders are defined as those who do not present any of the above criteria.

Exclusion Criteria:

* presence of diagnosed genetic conditions known to alter energy metabolism and/or nutrition;
* presence of diagnosed eating disorders;
* habitual use of supplements known to alter energy metabolism and/or nutrition;
* concomitant use of drugs known to alter energy metabolism and/or nutrition.

Where it's running

  • IRCCS Eugenio Medea
    Bosisio Parini, Lc, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.